Startup ‘Device/Data/Drug’ Medtech Company Begins Operations

Last year wasn’t a complete write-off. Despite the global pandemic, seasoned life sciences entrepreneur Richard J. Linder founded a medtech company aimed at developing new wireless technologies and techniques for interventional cardiology, interventional radiology, and neurointerventional radiology. Xenter Inc. recently formally launched in Salt Lake City, Utah.

Xenter is launching a digital health platform that will leverage new wireless interventional devices that provide physiologic data and images simultaneously and enable patients to have access and control of their medical data. The Xenter platform will enable novel therapeutic drug research by combining Physical Intelligence™ data with historical health data and other relevant information provided by patients and other patient-authorized sources.
 
According to Linder, Xenter is developing radically innovative medical devices using Xenter’s sensors and signals technology that enables wireless physiologic data collection, wireless intravascular imaging, and software technologies for the treatment of heart and vascular disease. The company has assembled a cast of medical scientists, cellular biologists, pharmacologists, electrical engineers, mechanical engineers, researchers, practitioners and some of the world’s most experienced and accomplished entrepreneurs and industry veterans, which will be announced shortly.

“I founded Xenter to develop and deliver a groundbreaking platform for wireless imaging and physiologic data collection to physicians worldwide using entirely new medical devices and systems, to enable patients to own and monetize their medical information, and solve some of the most complex problems associated with medicine and healthcare,” said Linder, founder, chairman and CEO. “The future of medicine lies at the crossroads of regenerative medicine, new data collection techniques to facilitate targeted therapeutic drug development, combination devices that utilize novel therapeutics delivered by new devices, and new sensors and signals technologies utilized in hospitals and outpatient care settings.”
 
“We are bringing the world’s leading medical experts to Xenter in order to drive dynamic changes to interventional medicine, therapeutic drug development, and digital health technology globally,” he said.
 
Xenter’s next-generation devices will integrate functions that formerly required multiple costly devices. Xenter expects the resulting instrumentation and strategies to drive a generational improvement in the efficiency and effectiveness of interventional medicine.
 
On an ongoing basis, vast amounts of data are collected from clinical trials and real-world experience with drugs and devices from medtech, pharma and biotech. Previously, these data have been focused on specific clinical studies. Xenter will capitalize on this opportunity to harness larger amounts of information in its Physical Intelligence data sets for improved target drug discovery and design, clinical trial strategy, patient recruitment, trial site selection, clinical trial monitoring and overall decision making. Unlocking the potential in Physical Intelligence data sources, including biomarker, genomic, electronic health records (EHRs), claims data, real world data and clinical trial data will drive improved device and drug development and lead to breakthrough medicines that will make a meaningful improvement in the lives of patients around the world.
 
Linder is a seasoned entrepreneur who has founded or co-founded multiple successful medical device companies and held leadership and CEO roles in several leading biotechnology organizations. Linder has also been instrumental in advancing the life science industry, both at large and specifically in the Utah ecosystem. He is the founder and Chairman Emeritus of BioUtah, Utah’s independent life science association representing Utah’s medical device, drug discovery and diagnostic companies. 
 
The team’s first innovation, which Xenter will announce shortly, is a medical device that will revolutionize the field of interventional medicine by producing valuable Physical Intelligence data and enabling advanced artificial intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.